Huntington's disease (HD) is an inherited neurological disorder that results in the progressive degeneration of cells in the brain. Symptoms often start with abnormal movements and mood swings in the body's voluntary muscles, which are caused by the breakdown of certain neurons. Over time, the affected areas of the brain deteriorate, leading to the development of further neurological and physical symptoms. HD is a complex genetic disorder that affects a person's physical and cognitive abilities. Studies suggest that a mutation in a gene called Huntingtin, which is responsible for producing an essential protein, is the cause of HD. This mutation leads to abnormally long or repetitive DNA sequences in the Huntingtin gene, causing it to produce an altered or toxic form of the Huntingtin protein, which then results in the death of neurons in specific areas of the brain. Aside from physical and cognitive problems, people with HD also experience psychiatric issues, such as depression, irritability, aggression, and compulsive and addictive behavior. These symptoms can be particularly hard to manage due to the complex nature of the underlying disorder. Therefore, effective treatment of HD must address not only the physical and cognitive symptoms, but the behavioral and psychological ones as well. Medications, such as dopaminergic drugs and antidepressants, may be used to manage some of the behavioral and psychological symptoms of HD. Physical therapy, occupational therapy, and speech therapy can help with the physical and cognitive changes caused by the disorder. Additionally, cognitive behavioral therapy can help people with HD manage their behaviors and cope with the changes that the disease brings. HD is a progressive disorder, and as such, is incurable. However, with early diagnosis, ongoing management, and supportive care, people with the disease can lead relatively normal lives for many years.
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : In silico in vitro and in vivo study of geraniol role in Alzheimer's disease
Bhuvanesh Baniya, Mohanlal Sukhadia University, India
Title : Prince transform: a wave-mechanical framework for real-time EEG analysis and early seizure prediction using chirp and drift detection
Mustafa A Khan, Sevaro Health Inc., United States
Title : Gut-brain axis in autism spectrum disorder: MicroRNAs as a critical mediator of pathogenesis
Rahem Rahmati, Shahrekord University of Medical Sciences, Iran (Islamic Republic of)